Rare Disease Report
Physicians
Physicians
Patients & Caregivers

Study Administers IMG-7289 to First Patients with Myelofibrosis

SEPTEMBER 20, 2017
Mathew Shanley
The first patients have been dosed in a Phase 1/2 clinical trial of IMG-7289 for the treatment of myelofibrosis (MF), according to Imago BioSciences.

The clinical-stage pharmaceutical company is developing novel therapies for hematological and inflammatory diseases. Myelofibrosis is characterized by the production of inflammatory cytokines, and IMG-7289 is an investigational lysine-specific demethylase 1 (LSD1) inhibitor intended to suppress that production.

Myelofibrosis is a serious, life-limiting blood cancer that often results in extensive scarring in the bone marrow. That scarring prevents the normal production of blood cells, and can lead to anemia, fatigue, and an increased risk of bleeding and infection. Other common symptoms include pale skin, bruising, night sweats, an enlarged spleen, fever, and bone pain.

The clinical trial (NCT03136185) is being conducted at multiple locations in Australia, and is expected to evaluate the safety, pharmacokinetics, and pharmacodynamics of the orally administered IMG-7289 in patients with high-risk myelofibrosis ages 18 and older.

"Myelofibrosis remains a devastating and deadly disease, with an urgent need for therapies that alter disease progression and impact survival," said Hugh Young Rienhoff, Jr. M.D., Imago's Chief Executive Officer in a press release.

"By targeting an enzyme specifically regulating myeloid cell gene transcription, IMG-7289 has significant disease-modifying activities in multiple non-clinical models of myelofibrosis and thus offers the possibility to influence the natural history of this disease.”

The primary outcome measure of the multi-center, open label study will assess the safety and tolerability of the drug in patients from the time of first dose through 28 days after the completion of treatment. These factors will be measured via the frequent monitoring of adverse events (AEs), physical examination, as well as vital signs and laboratory parameters.

Secondary outcome measures include drug concentration for up to 3 months.

There are an estimated 18,000 patients in the United States affected by myelofibrosis. Today is Myelofibrosis Awareness Day, one of the many parts of MPN Blood Cancer Awareness Month, and more information on how to spread awareness of this and other related conditions can be found by visiting the MPN Research Foundation website.

For more updates throughout MPN Blood Cancer Awareness Month, follow Rare Disease Report on Facebook and Twitter.

Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.